Pulmonx Corporation

Canaccord Genuity acts as Lead Manager for upsized US$218.5 million initial public offering of common stock by Pulmonx Corporation.

Canaccord Genuity is pleased to announce that on October 5, 2020, it completed an upsized initial public offering of common stock for Pulmonx Corporation (NASDAQ: LUNG) (the “Company”). The Company issued a total of 11,500,000 shares of its common stock at a price to the public of $19.00 per share, above the initial range of $14.00 to $16.00 per share and the revised range of $17.00 to $18.00 per share, and includes the full exercise of the underwriters’ overallotment option. The gross proceeds to the Company, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $218.5 million. The Company intends to use the net proceeds from the offering to hire additional sales and marketing personnel, expand marketing programs in the US, Europe and Asia Pacific, fund product development and research activities and for working capital and general corporate purposes, including acquisitions or strategic investments in complementary businesses or technologies.

Canaccord Genuity acted as Lead Manager for the offering.

Pulmonx Corporation develops planning tools and treatments for obstructive lung disease. The Company’s solutions provides bronchoscopic lung volume reduction without surgery and its associated risk and is used to treat patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for alternative surgical approaches.